Al Ozonoff
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Year:
2026
Year:
2026
Year:
2025
Background and Objective Rates of neonatal opioid withdrawal syndrome (NOWS) among infants and opioid-related hospitalizations among adults have increased in recent decades. We examined rates of NOWS births and opioid-related hospitalizations among adult females of childbearing age overall and by sociodemographic and geographic factors using hospitalization data. Methods We used data from the New York State Inpatient Database for 2018 from the Healthcare Cost and Utilization Project. We identified infants with NOWS and opioid-related hospitalizations using diagnosis codes and calculated rates of NOWS per 1,000 live births and opioid-related hospitalizations per 1,000 hospitalizations among females of childbearing age. We compared rates by geographic and sociodemographic factors and examined the correlation between county-level rates. Results The NOWS rate was 4.66 per 1,000 live births, while the rate of opioid-related hospitalizations was 36.6 per 1,000 hospitalizations. There was variation by county and sociodemographic factors including urban-rural classification, race and ethnicity, insurance payer, and median income. We found the highest rates for both NOWS and opioid-related hospitalizations in non-metropolitan areas, among patients with public insurance, and among non-Hispanic White or Native American populations. There was a significant linear correlation (r=0.28; p =0.03) between county-level rates; however, only 32% of counties were concordant in quartiles for both measures. Conclusion Our findings indicate variation in rates of NOWS and opioid-related hospitalizations by geographic and sociodemographic factors, with only moderate concordance in county-level rates. These findings may provide a nuanced interpretation by examining measures impacting both women and infants and have important implications in prioritizing treatment access.
Year:
2025
Background: Newborns are at increased risk of vaccine preventable morbidity and mortality. The American Academy of Pediatrics recommends administering the birth dose of the hepatitis B vaccine (HBV) between 0 and 30 days of life [based on birth weight (BW) < 2000 g vs. ≥ 2000 g], followed by several vaccines at 2 months of age (regardless of the BW) including the first dose of the pneumococcal vaccine (PCV). However, adherence to these guidelines is often suboptimal, resulting in incomplete or delayed vaccination. Methods: This is a 10-year retrospective, single-center observational study examining the rates and timeliness of HBV and PCV vaccination of infants admitted to the mother-baby unit and neonatal intensive care unit (NICU) from 2013 to 2023. Multinomial logistic regression was used to examine factors associated with vaccination status. Results: HBV vaccination of infants admitted to the neonatal intensive care unit (n = 4935) was significantly more likely to diverge from American Academy of Pediatrics recommendations versus HBV vaccination of infants admitted to the mother-baby unit (n = 49,857). Factors associated with higher relative risk of delayed HBV vaccination included administration in the pre-COVID prepandemic era, prematurity, BW ≥ 2000 g and Black/African American race, with the latter two also being associated with incomplete vaccination at discharge. For PCV, Hispanic patients were more likely to be discharged with incomplete vaccination compared with non-Hispanic patients. Conclusions: Postpandemic, there were lower rates of delayed vaccinations, possibly reflecting increased vaccine awareness among parents and providers. Preterm status was a key factor influencing HBV vaccination timeliness. Perceptions and attitudes toward early-life vaccination, including potential racial biases, should be examined as potential contributors to differing vaccine administration practices.
Year:
2025
Detection and diagnosis of bloodborne pathogens are critical for patients and for preventing outbreaks, yet challenging due to these diseases’ nonspecific initial symptoms. We previously advanced CRISPR-based Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN) technology for simultaneous detection of pathogens on numerous samples. Here, we develop three CARMEN panels that target viral hemorrhagic fevers, mosquito-borne viruses, and sexually transmitted infections, collectively identifying 23 pathogens. We use deep learning to design CARMEN assays with enhanced sensitivity and specificity, validating them and evaluating their performance on synthetic targets, spiked healthy normal serum samples, and patient samples for Neisseria gonorrhoeae in the United States and for Lassa and mpox virus in Nigeria. Our results show multiplexed CARMEN assays match or outperform individual assay RT-qPCR in sensitivity, with matched specificity. These findings underscore CARMEN’s potential as a highly effective tool for accurate pathogen detection for clinical diagnosis and public health surveillance.
Year:
2025
Yellow fever virus (YFV), a mosquito-borne flavivirus that causes severe hemorrhagic disease, is endemic in parts of South America and Africa, yet genomic data from Sierra Leone is lacking despite ongoing surveillance. Using hybrid-capture metagenomic sequencing, we generated a complete 10,611-bp YFV genome (98% coverage) from an adult male patient who reported to the Kailahun Government Hospital with fever and muscle pain. Phylogenetic analysis assigned the genome to West African Clade V via the YFV Nextstrain build. Compared with other West African isolates, the Sierra Leone genome contained 57 substitutions, three of which were non-synonymous (NS2b: N79S, NS3: V515I, and RdRp: A643V). Bayesian phylogenetics estimated the time to the most recent common ancestor with the closest sequences from Senegal and the Netherlands as January 14, 2001 (95% HPD: December 17, 1987 - April 28, 2009), suggesting long-standing, cryptic transmission. Together, these findings underscore the need for expanded genomic surveillance to monitor YFV spread, evolution, and potential impacts on vaccine performance.
Year:
2025
In January 2025, Sierra Leone reported its first mpox case in eight years, followed by a rapid nationwide surge that made it the epicenter of the continental mpox virus (MPXV) Clade IIb A.2.2 outbreak, with more than 5,000 confirmed cases reported by August. To investigate the origin, timing, and spread of this epidemic, we generated 338 high-quality MPXV genomes from cases across 14 districts and conducted Bayesian phylogeographic analyses. We found that transmission was driven by a newly emerging Clade IIb lineage, G.1, descended from lineages circulating in the ongoing Nigerian epidemic. Phylogeographic reconstructions indicate that G.1 arose in late September 2024 and circulated undetected for approximately three months before establishing sustained transmission in the densely populated Western Area Urban and Rural districts, which became the principal source of repeated viral introductions that drove epidemics in other regions. Together, these findings reveal the origins and dispersal dynamics of the 2025 mpox outbreak in Sierra Leone and underscore that effective control remains achievable through targeted vaccination, strengthened early warning systems, and improved access to genomic and diagnostic surveillance.
Year:
2025
In early 2025, Sierra Leone experienced a large outbreak of mpox clade IIb, underscoring the urgent need for portable, low-cost diagnostics in decentralized settings. We rapidly developed and field-deployed Mpox SHINE, a CRISPR–Cas13 assay that integrates lyophilized reagents, ambient-temperature lysis, and automated fluorescence detection on a portable device, the DxHub. The assay achieved analytical sensitivity down to 10 copies/µL with minimal hands-on time. In-country evaluation of 56 clinical specimens showed complete concordance with qPCR, with 100% sensitivity (45/45) and 100% specificity (11/11) at the sample level. Mpox SHINE also detected the virus directly from unextracted lesion swabs, maintaining 100% sensitivity and specificity in 16 samples (8 positive, 8 negative). Across extracted and unextracted samples, the mean time-to-result was ∼35 minutes, with all positives detected within 45 minutes. Thus, Mpox SHINE performed on the DxHub demonstrates how CRISPR-based pathogen detection can be rapidly translated into portable tools for the front lines of outbreak response. Teaser CRISPR-Cas13 assay and portable device bring rapid, reliable mpox testing to outbreak settings.
Year:
2025
Background Predicting mortality risk in patients with COVID-19 remains challenging, and accurate prognostic assays represent a persistent unmet clinical need. We aimed to identify and validate parsimonious transcriptomic signatures that accurately predict fatal outcomes within 48 hours of hospitalization. Methods We studied 894 patients hospitalized for COVID-19 across 20 US hospitals and enrolled in the prospective Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) with peripheral blood mononuclear cells (PBMC) and nasal swabs collected within 48 hours of admission. Host gene expression was assessed by RNA sequencing, nasal SARS-CoV-2 viral load was measured by RT-qPCR, and mortality was assessed at 28 days. We first defined transcriptional signatures and biological features of fatal COVID-19, which we compared against mortality signatures from an independent cohort of patients with non-COVID-19 sepsis (n=122). Using least absolute shrinkage and selection operator (LASSO) regression in 70% of the COVID-19 cohort, we trained parsimonious prognostic classifiers incorporating host gene expression, age, and viral load. The performance of single and three-gene classifiers was then determined in the remaining 30% of the cohort and subsequently externally validated in an independent, contemporary COVID-19 cohort (n=137) with vaccinated patients. Results Fatal COVID-19 was characterized by 4189 differentially expressed genes in the peripheral blood, representing marked upregulation of neutrophil degranulation, erythrocyte gas exchange, and heme biosynthesis pathways, juxtaposed against downregulation of adaptive immune pathways. Only 7.6% of mortality-associated genes overlapped between COVID-19 and sepsis due to other causes. A COVID-specific three-gene peripheral blood classifier ( CD83, ATP1B2, DAAM2 ) combined with age and SARS-CoV-2 viral load achieved an area under the receiver operating characteristic curve (AUC) of 0.88 (95% CI 0.82–0.94). A three-gene nasal classifier ( SLC5A5, CD200R1 , FCER1A ), in comparison, yielded an AUC of 0.74 (95% CI 0.64-0.83). Notably the expression of OLAH alone, a gene recently implicated in severe viral infection pathogenesis, yielded an AUC of 0.86 (0.79–0.93). Both peripheral blood classifiers demonstrated comparable performance in vaccinated patients from an independent external validation cohort (AUCs 0.74– 0.80). Conclusions A three-gene peripheral blood signature, as well as OLAH alone, accurately predict COVID-19 mortality early in hospitalization, including in vaccinated patients. These parsimonious blood- and nasal-based classifiers merit further study as accessible prognostic tools to guide triage, resource allocation, and early therapeutic interventions in COVID-19.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (49)
Holden T. Maecker
Stanford University School of Medicine
Suzanna Chak
University of California, San Francisco
Elsio Wunder
Assistant Professor
University of Connecticut
Slim Fourati
Assistant Professor
Northwestern University Feinberg School of Medicine
Andrew Rambaut
Professor
University of Edinburgh
Bali Pulendran
Emory University
Hanno Steen
Professor
Harvard Medical School
david o'connor
Professor
University of Wisconsin-Madison
Daniel Park
Group Leader
Broad Institute
Samuel Yang
Faculty
Stanford University
Christopher B. Fox
Associate Dean of Research
Utah State University
Stephen Schaffner
Senior Computational Biologist
Broad Institute
Mehmet Saluvan
Sr. Staff Scientist
Boston Children's Hospital
Joann Diray Arce
Assistant Professor
Boston Children's Hospital
Albert Ko
Professor of Medicine
Yale University
Jeffrey A. Hubbell
University of Chicago
Alvin Kho
Assistant Professor
Harvard University
Elyse Stachler
Broad Institute of MIT and Harvard
Ramin Salehi-Rad
UCLA
Kristian Andersen
Professor
Scripps Research Institute
Abroon Qazi
american university of sharjah
Catherine Blish
Association Professor
Stanford University School of Medicine
Akiko Iwasaki
Professor
Yale University School of Medicine
William Messer
Associate Professor
Oregon Health & Science University
Matthew F. Krummel
University of California, San Francisco
Scott Brakenridge
Professor
University of Washington
Michael Wilson
Professor
University of California, San Francisco
Cole Maguire
University of Texas at Austin
Harm van Bakel
Associate Professor
Icahn School of Medicine at Mount Sinai
Elaine F. Reed
University of California
Linda N. Geng
Stanford University
Harlan Krumholz
Professor of Medicine
Yale University
Lekshmi Santhosh
Associate Professor
University of California
Aleksandra Leligdowicz
Assistant Professor
University of Western Ontario
Lawrence Charles Madoff
Professor
University of Massachusetts Chan Medical School
Matthew A. Pettengill
Thomas Jefferson University Hospital
Simon van Haren
Assistant Professor of Pediatrics
Harvard University
Angela Rogers
Professor
University of Texas Southwestern Medical Center
Lydia Krasilnikova
Broad Institute
Laura Luebbert
Broad Institute
Hiromitsu Asashima
University of Tsukuba
David Scott
Dana-Farber Cancer Institute
Joshua Levy
Project Scientist
Scripps Research Institute
George A Yendewa
Assistant Professor
Case Western Reserve University School of Medicine
Lauren Ehrlich
Professor
University of Texas at Austin
Nathan Grubaugh
Associate Professor
Yale School of Public Health
Michele Kutzler
Professor of Medicine and Microbiology and Immunology
Drexel University
David Dowling
Principal Investigator, Adjuvant, Innovation, Discovery and Development (AIDD) Lab
Boston Children's Hospital
Erin Scherer
Associate Professor
Emory University
Make your next move.
Prepare your application
Review drafts before you send them.